Back

Risk of ischemic stroke, hemorrhagic stroke, bleeding, and death in patients switching from warfarin to dabigatran after an ablation

30 August 2016 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Best Posters session 6 - Best Posters in atrial fibrillation ablation Catheter ablation ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Jannik Langtved Pallisgaard

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Professor D. Scherr (Graz, AT)
Abstract Slides
Presentation thumbnail
Professor Y. De Greef (Antwerp, BE)
Abstract Slides
Presentation thumbnail
Doctor J. Kim (Ansan-Si, KR)
Abstract Slides

Access the full session

Session thumbnail
Best Posters session 6 - Best Posters in atrial fibrillation ablation

The Event

Event poster

ESC Congress 2016

30 August 2016 08:30 CET
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
25 August 2023
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020
thumbnail
Congress Presentation
Balancing stroke and bleeding risks: the impact of stopping anticoagulation after aAF ablation - a systematic review and meta-analysis
1 September 2025
thumbnail
Congress Presentation
Discontinuation of oral anticoagulation after successful atrial fibrillation treatment with radiofrequency and pulsed-field ablation
13 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources